Lauren E. Abrey and Andrew D. Zelenetz received research funding from Biogen IDEC. Biogen-IDEC provided the drug and financial support.
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
Article first published online: 11 OCT 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 11, pages 2528–2534, 1 December 2007
How to Cite
Iwamoto, F. M., Schwartz, J., Pandit-Taskar, N., Peak, S., Divgi, C. R., Zelenetz, A. D., Humm, J. and Abrey, L. E. (2007), Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer, 110: 2528–2534. doi: 10.1002/cncr.23077
- Issue published online: 19 NOV 2007
- Article first published online: 11 OCT 2007
- Manuscript Accepted: 13 JUL 2007
- Manuscript Revised: 8 JUN 2007
- Manuscript Received: 30 MAR 2007
- non-Hodgkin lymphoma;
- radiation dosimetry;
- blood-brain barrier;
- monoclonal antibodies
Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood–brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenous radioimmunotherapy using anti-CD20 antibody can be delivered to PCNSL.
This was a single-institution prospective study. Indium-111 ibritumomab tiuxetan was used for imaging and dosimetry. Yttrium-90 ibritumomab tiuxetan at doses of 0.3 to 0.4 mCi/kg were subsequently given for the treatment of recurrent or refractory PCNSL. 111In data were used to estimate radiation doses to lesions delivered by 90Y ibritumomab tiuxetan therapy.
Six patients (4 men, 2 women) with a median age of 60 years and median Karnofsky performance status of 70 received both indium-111 and yttrium-90 ibritumomab tiuxetan. The median absorbed dose delivered to the CNS lymphoma was 701 cGy compared with 70 cGy to normal brain. The median progression-free and overall survival times were 6.8 weeks and 14.3 weeks, respectively.
The results from this study suggest that it may be feasible to deliver radiolabeled monoclonal anti-CD20 antibodies as a component of therapy for PCNSL. Cancer 2007. © 2007 American Cancer Society.